TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Gliobl… (NCT07668869) | Clinical Trial Compass
RecruitingNot Applicable
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
Poland92 participantsStarted 2025-12-30
Plain-language summary
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation.
The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 years
* Karnofsky Performance Status ≥70
* Histologically confirmed IDH-wildtype glioblastoma
* First, second, or third recurrence
* Radiological recurrence according to RANO 2.0 criteria
* Prior radiotherapy and temozolomide treatment
* At least 6 months since completion of previous radiotherapy
* Contrast-enhancing recurrent lesion visible on MRI
* Maximum recurrent lesion diameter ≤5 cm
* Available molecular profile including IDH and MGMT status
* Adequate hematologic, renal, and hepatic function
* Written informed consent
Exclusion Criteria:
* Previous bevacizumab treatment
* Planned chemotherapy or targeted therapy after study intervention
* Previous stereotactic re-irradiation within the planned treatment field
* More than three recurrences
* Significant psychiatric disorders
* Significant unrelated neurological disease
* Implanted pacemaker, defibrillator, deep brain stimulator, or other incompatible electronic device
* Pregnancy or breastfeeding
* Active intracranial hemorrhage
* Uncontrolled hypertension
* Severe renal dysfunction
* Participation in another interventional study likely to interfere with this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
One-Year Overall Survival Rate
Timeframe: 12 months after randomization
Trial details
NCT IDNCT07668869
SponsorProf. Franciszek Lukaszczyk Memorial Oncology Center